000			01801 a2200517 4500
005			20250514215308.0
264		0	_c20050330
008			200503s 0 0 eng d
022			_a0007-0920
024	7		_a10.1038/sj.bjc.6602301 _2doi
040			_aNLM _beng _cNLM
100	1		_aDearnaley, D P
245	0	0	_aPhase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. _h[electronic resource]
260			_bBritish journal of cancer _cFeb 2005
300			_a488-98 p. _bdigital
500			_aPublication Type: Clinical Trial; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
650	0	4	_aAdenocarcinoma _xradiotherapy
650	0	4	_aAged
650	0	4	_aAndrogen Antagonists _xtherapeutic use
650	0	4	_aCyproterone _xtherapeutic use
650	0	4	_aHumans
650	0	4	_aMale
650	0	4	_aMaximum Tolerated Dose
650	0	4	_aMiddle Aged
650	0	4	_aNeoadjuvant Therapy
650	0	4	_aPilot Projects
650	0	4	_aProstate-Specific Antigen _xblood
650	0	4	_aProstatic Neoplasms _xradiotherapy
650	0	4	_aRadiation Injuries
650	0	4	_aRadiotherapy Dosage
650	0	4	_aRadiotherapy, Conformal _xadverse effects
650	0	4	_aRectum _xradiation effects
650	0	4	_aTreatment Outcome
650	0	4	_aUrinary Bladder _xradiation effects
700	1		_aHall, E
700	1		_aLawrence, D
700	1		_aHuddart, R A
700	1		_aEeles, R
700	1		_aNutting, C M
700	1		_aGadd, J
700	1		_aWarrington, A
700	1		_aBidmead, M
700	1		_aHorwich, A
773	0		_tBritish journal of cancer _gvol. 92 _gno. 3 _gp. 488-98
856	4	0	_uhttps://doi.org/10.1038/sj.bjc.6602301 _zAvailable from publisher's website
999			_c15362461 _d15362461